Novel checkpoint inhibitors hit by another setback, but opportunities remain
A trial of novel checkpoint inhibitor monalizumab has been terminated after the drug failed to meet the efficacy threshold.
By
A trial of novel checkpoint inhibitor monalizumab has been terminated after the drug failed to meet the efficacy threshold.
ByThe geographic disparities behind early-onset dementia highlight the need to bridge the urban-rural divide.
ByWith the 20th birthday of the renowned Clinical Trial Supply East Coast conference in October, we look at topic changes…
ByThe latest figure is higher than the 49.7% of companies who were hiring for industrial automation related jobs a year…
ByThe frequency of sentences related to AI between July 2021 and June 2022 was 421% higher than in 2016.
ByThe Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
ByThe latest figure is higher than the 42.4% of companies who were hiring for future of work related jobs a…
ByFour Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five…
ByThank you for subscribing to Clinical Trials Arena